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We report a molecular modeling study aimed to locate and provide the full structural characteristics of the
exosite binding site of the BACE1. A three-step procedure was followed. In the first stage, we performed
blind docking studies on the whole target surface. In a second stage, the mode of binding was further refined
by molecular dynamics (MD) simulation. Finally, binding free energy calculations, through the MM-PBSA
protocol, were carried out to gain insight into the stability and thermodynamics of the inhibitor located at the
selected binding pockets. Twelve binding pockets were identified on the surface of BACE1 by blind docking
studies. The calculations of binding free energies for the 12 complexes show that van der Waals interactions
dominate the mode of binding of these complexes. The best ranked complex shows that residues Glu255-
Pro258, Phe261, Gly264-Ala272, Asp311-Ala313, Ser315, and Asp317-Tyr320 are located within ∼6 Å from
the INH located at the exosite. The hydrogen bonds formed between the INH peptide, residues Tyr1, Tyr3,
and Leu7 with the BACE1 residues Leu267, Cys269, Trp270, Asp311, and Asp 317 can strengthen the binding
of the BACE1-INH complex.
1. Introduction
Alzheimer disease (AD) is a degenerative brain syndrome
first described by Alois Alzheimer in 1906, which affects more
than 37 million people worldwide.1 Although the etiology
remains enigmatic, AD appears to be brought about by genetic
and nongenetic factors. There are two main theories in relation
to AD treatment. The “cholinergic hypothesis” relates the
neurodegeneration to the loss of cholinergic neurotransmission,
while the current “amyloid hypothesis” correlates the increased
A production or reduced A clearance to the formation of A
deposits, leading to the progression of the AD.2-6 A is
generated in vivo through proteolytic cleavage of the membrane-
anchored -amyloid precursor (APP) by the -site amyloid
cleaving enzyme (BACE1) (also called -secretase, memapsin
2, or ASP-2).7-16
BACE1 has long been regarded as a therapeutic target for
AD in the development of inhibitor drugs for reduction of A.
The cloning and identification of BACE1, first reported in
1999,17-21 invigorated research on both the protease and its
inhibitor drugs in many laboratories around the world.22-27 The
bilobal structure of BACE1 has the conserved general folding
of the aspartic proteases superfamily and more precisely the
pepsin subfamily.17-20 The crystal structures of BACE1 confirm
that the active site is a long cleft for the substrate recognition
with two catalytic aspartic residues.28,29 Kinetic and specificity
studies showed that BACE1 interacts with approximately 11
substrate residues, with affinity to many hydrophobic residues
but somewhat broad in specificity.30,31
In addition to the active site, some proteolytic enzymes
contain additional binding pockets, termed exosites, which
engage substrates at locations distal to the active site.32-36 These
binding pockets can contribute significantly to the stabilization
of the enzyme-substrate binary complex by providing important
structural determinants of interaction. Additionally, exosites on
some proteolytic enzymes can act as allosteric regulators of the
enzyme activity through conformational changes to the active
site, in order to cause an augmentation or diminution of the
enzyme’s catalytic reactivity. In some cases, molecules bind to
an exosite of a protease, proving to be effective modulators of
enzymatic activity.34,35 Hence, exosites represent an alternative
target for regulatory ligands binding to proteolytic enzymes.
Because the exosites are structurally distinct from the active
sites of these enzymes, the nature of the molecules that bind to
the exosites may be different from that of active-site-directed
inhibitors. Therefore, it is possible that in some cases the exosite
could provide a more pharmacologically tractable target for
small molecule interactions than does the active site of the
enzyme. Finally, the structural diversity of exosites among
related enzymes may be greater than that of the enzyme active
sites, thus potentially providing a means for the development
of highly selective modulators.
While exosites were reported for serine and cysteine pro-
teases, few examples of exosites have been reported for aspartyl
proteases.36,37 Kornacker et al. reported the discovery of an
exosite within the catalytic domain of the human BACE1 that
binds small peptides in a manner that is unaffected by active
site ligand occupancy.37,38 Peptides that bind in this exosite
inhibit the ability of BACE1 to hydrolyze its natural protein
substrate, APP. The size of these peptides and the nature of the
amino acids required for binding to this pocket suggest that it
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may be possible to inhibit the catalytic activity of BACE1 by
binding small, drug-like molecules to this exosite.37,38 It is clear,
therefore, that the knowledge of the structural details of this
exosite is of paramount importance for the design and develop-
ment of new inhibitors.
Despite the importance of this regulatory mechanism, there
is in fact only limited and partial structural information of this
exosite.37,38 Thus,althoughthecrystalstructureof theenzyme-sub-
strate-inhibitor ternary complex has been determined,38 to our
knowledge, it is not in the public domain. In the present work,
we present a molecular modeling study aimed to locate and
provide the full structural characteristics of the exosite binding
pocket of BACE1. We performed blind docking studies,
followed by molecular dynamics (MD) simulation, in order to
refine the mode of binding. Finally, binding free energy
calculations were carried out to gain insight into the structure,
binding mode, stability, and thermodynamics of the inhibitor
located at the BACE1 exosite binding pocket.
2. Methods
Enzyme Substrate Model (ES). Coordinates of BACE1
determined at 2.1 Å resolution in complex with the peptido-
mimetic substrate OM00-3 (Glu-Leu-Asp-Leu-(CH(OH)-CH2)-
Ala-Val-Glu-Phe, where (-CH(OH)-CH2-) depicts the hy-
droxyethylene isostere of the peptide bond) were downloaded
from the PDB database39 (entry 1M4H29) and used as a structural
template.
Simulations were performed in the presence of the peptido-
mimetic substrate modeled as an all-trans Glu-Leu-Asp-Leu-
Ala-Val-Glu-Phe peptide. The B chain and all water molecules
were removed from the PDB file. Particular attention was given
to the ionization state of the active site, which contained the
aspartyl dyad (Asp32/Asp228). At optimal pH for enzymatic
activity (∼3.5-4.5),40 the aspartyl dyad is most probably
monoprotonated in the uncomplexed enzyme as well as in the
complex with the substrate. In this study, the ionizable residues
were modeled in the protonation state corresponding to pH 4.5
obtained using the H++ software.41-43 Asp32 was protonated
on the basis of the computed pKa on the 1M4H X-ray structure.
The protonation of Asp32 was also suggested by a previous
MD and docking study.44 Although a recent quantum-chemical
study suggests dideprotonated and monoprotonated states for
the free and complexed forms of BACE1, respectively,45
dideprotonation is in contradiction with the accepted reaction
mechanism of pepsin-like enzymes,46,47 which requires that one
of the aspartic residues be protonated.
Inhibitor Peptide (INH). The peptide Ac-Tyr-Pro-Tyr-Phe-
Ile-Pro-Leu-NH2 (INH), initially identified from a combinatorial
phage peptide library,37 was selected to model the inhibitor. This
INH represents a minimal peptide that retains good binding
affinity to BACE and binds the exosite pocket with Kd ) 1.2
µM,38 forming a ternary complex with the ES species in a
noncompetitive way with respect to the substrate.37,38 Therefore,
this peptide becomes an excellent candidate to carry out the
“blind docking” analysis.
Blind Docking. Molecular docking48,49 as implemented in the
AutoDock program50 was performed. The docking of the INH
was carried out on the entire protein surface without prior
specification of the binding site (“blind docking”).51-56 Starting
from a snapshot taken at 10 ns of a previously equilibrated ES
system (data not shown), following the same MD conditions
listed below (see Binding Mode in the Methods section),
AutoDock 3.0.5 was used to dock the INH to the ES surface
using a Lamarckian genetic algorithm with pseudo-Solis and
Wets local search.50
The following parameters were used: the initial population
of trial ligands was constituted by 250 individuals; the maximum
number of generations was set to 2.7 × 104. The maximum
number of energy evaluations was 10.0 × 106. All other run
parameters were maintained at their default setting. The 3D
affinity map was a cube with 126 × 126 × 126 points separated
by 0.6 Å and centered at the ES complex. Polar hydrogen atoms
and charges were added to the ES and INH models using
AutoDock.50 The exact same preparation and docking processes
were applied to eight different AutoDock jobs starting each one
with the fully flexible ligand from each corner of the affinity
cube. The docking procedure was applied to the whole ES
surface, without imposing any binding site. The resulting docked
conformations were clustered into families by the backbone
rmsd. The lowest docking-energy conformation of each family
was considered the most favorable orientation.57
Binding Mode. After the blind docking process, the coor-
dinates of the lowest energy structure of each ES-INH ternary
complex were extracted and subjected to molecular dynamics
(MD). All MD simulations were done with the Amber package58
using the Duan et al. force field.59 The solvent effects were taken
into account through the generalized Born model developed by
Onufriev et al.60,61 The surface area was included in the solvation
term and has been computed using the LCPO model.62 A
monovalent electrostatic ion screening of 0.2 M was used.63 The
SHAKE algorithm64 was employed to constrain all hydrogen
atoms, leading to a 2.0 fs time increment. The temperature was
maintained using the Langevin thermostat65,66 with a collision
frequency of 2.5 ps-1. A 99 Å cutoff was set to the long-range
nonbonded interactions. The geometries were first energy-
optimized to remove possible bumps. Conjugate gradient energy
minimizations were performed three times using positional
restraints to all CR atoms with 500, 100, and 0 kcal/(mol Å)
force constants, in sequence. Further, the unrestrained system
was heated from 10 to 298 K over 25 ps. Finally, 2.0 ns
production runs were generated by MD simulations, collecting
snapshots every 1 ps. For each simulation, the analyses were
done over the last 1.0 ns.
Binding Energy Calculations. The MM-PBSA protocol was
applied to each MD trajectory in order to calculate the relative
binding energies of the ES-INH ternary complexes. The MM-
PBSA method was used in a hierarchical strategy and the details
of this method have been presented elsewhere.67 This protocol
was applied to 100 equidistant snapshots extracted from the last
1.0 ns of simulation and was used within the one-trajectory
approximation. Briefly, the binding affinity for a complex
corresponds to the free energy of association written as
while the relative affinities for a ligand to different binding
pocket can be calculated as
In the MM-PBSA protocol, the binding affinity in eq 1 is
typically calculated using
∆Gbind ) Gcomplex - (Greceptor - Gligand) (1)
∆∆Gbind(1f2) ) ∆Gbind(2) - ∆Gbind(1) (2)
∆G ) ∆EMM + ∆Gsolv - T∆Ssolute (3)
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where ∆EMM represents the change in molecular mechanics
potential energy upon formation of the complex, calculated using
all bonded and nonbonded interactions. Solvation free energy
penalty, ∆Gsolv, is composed of the electrostatic component (GPB)
and a nonpolar component (Gnp):
∆GPB was calculated solving the linear Poisson-Boltzmann
(PB) equation by using the pbsa program.58 Dielectric constants
of 1 and 80 were used for the interior and exterior, respectively.
The hydrophobic contribution to the solvation free energy,
∆Gnp, is estimated using the equation
where SASA is the solvent-accessible surface area computed
by means of the linear combination of pairwise overlap (LCPO)
method62 with a solvent probe radius of 1.4 Å. The surface
tension proportionality constant R and the free energy of
nonpolar solvation for a point solute  were set to its standard
values, 0.00542 kcal/(mol ·Å2) and 0.92 kcal/mol, respectively.68
The entropic contribution to the free energy (T∆S) was
estimated by
where ∆Strans and ∆Srot are the entropy contributions from
translational and rotational motion calculated using classic
statistics mechanics.67 The entropy contribution from vibrational
motion (∆Svib) was obtained using normal mode calculations.
Prior to the normal mode calculations, each snapshot was
subjected to energy minimization using a distance dependent
dielectric function 4rij until a convergence lower than 10-4 kcal/
mol Å.69
Since entropy calculations for large systems are extremely
time-consuming, we applied this analysis to five snapshots taken
at intervals of 200 ps from the final 1.0 ns of the MD simulation.
It should be emphasized that the T∆S term is expected to be a
crude approximation of only the solute entropy.
The per-residue binding energy decomposition was performed
as explained elsewhere.70
The trajectories were analyzed using the ptraj module of the
Amber package.58 The buried surface areas reported in Table 1
were calculated from the solvent-accessible surface area (SASA)
using a probe radius of 1.4 Å with the NACCESS program.71
The buried areas upon binding were calculated as the difference
in the total SASAES-INH ternary complex and its components
divided by 2. The volumes reported in Table 1 were obtained
with the ARVO program,72 with a 3 Å protein film depth in the
binding sites. The depth of the binding sites was considered as
the distance between all ES atoms within 3 Å from the INH.
Ligand-protein contacts were analyzed with the ligand-protein
contact (LPC) software.73
Experimental Section. The binding stoichiometry for the
ES-INH ternary complexes, the dissociation constant (Kd),
measured by direct titration of BACE1 and carried out at pH
4.5 and 25 °C, the enthalpy (∆H), the entropy (∆S), and the
Gibbs free energy (∆G) of the reaction between the ES and
several 5-mer to 12-mer exosite binding peptides were obtained
by isothermal titration calorimetry experiments and published
elsewhere.37
The structural coordinates defining a three-dimensional
structure of a BACE1 exosite binding pocket are claimed in
ref 38. Kornacker et al.38 showed that the ES-INH ternary
complex crystallizes in the P212121 space group with one
BACE1 dimer per asymmetric unit. The final model includes a
BACE1 dimer, one Glu-Val-Asn-Phe-(CH(OH)-CH2)-Ala-Glu-
Phe peptide per molecule, 161 water molecules, and the exosite
peptide Ac-TTYPYFIP-NH2 in monomer A and the exosite
peptide Ac-YPYFIPL-NH2 (i.e., INH) in monomer B. Unfor-
tunately, to our knowledge, these coordinates are not in the
public domain.
3. Results and Discussion
Blind Docking. In the first stage, we carried out a preliminary
blind docking analysis using the Lamarckian genetic algorithm
on BACE1, a globular protein with more than 380 residues,
with the grid encompassing the whole BACE1 structure. Due
to the large protein accessible surface area, numerous putative
binding sites were found by the docking procedure (18 different
putative sites). The solutions were sorted in terms of ∆Gbind,
and the lowest docking energy conformations alone or the lowest
docking energy conformations included in the largest cluster
were considered to be the most stable orientations. Figure 1
shows the location of the 12 most representative and best ranked
INH binding sites found from the blind docking procedure.
Several parameters of these 12 putative binding sites have
been calculated as ∆Gbind, ∆∆Gbind, total, apolar, and polar
accessible surface area buried between the BACE1 and the INH
TABLE 1: Parameters for the Binding Sites Identified by “Blind Docking”
SASAb
complex Na total apolar polar volumec ∆Gbindd ∆∆Gbinde
C1 15 473.45 430.50 42.95 222.94 -11.64 0.00
C2 29 591.95 521.80 70.15 314.52 -11.41 0.23
C3 35 584.35 527.25 57.15 233.72 -10.61 1.03
C4 35 574.20 527.40 46.80 413.21 -10.47 1.17
C5 29 575.25 498.55 76.70 332.50 -10.37 1.27
C6 10 522.40 479.15 43.25 226.02 -10.12 1.52
C7 20 459.90 440.00 19.90 261.51 -9.98 1.66
C8 14 468.70 427.65 41.05 269.80 -9.94 1.70
C9 45 512.30 458.70 53.60 196.03 -9.93 1.71
C10 12 391.60 353.20 38.40 239.10 -9.72 1.92
C11 5 479.40 429.10 50.30 93.12 -9.34 2.30
C12 20 482.45 444.40 38.05 125.45 -9.02 2.62
a N is the number of results in the clusters. b Solvent-accessible surface area (Å2) buried upon binding. c In Å3. d Binding free energy (kcal/
mol) calculated with the AutoDock software. e Relative binding free energy (kcal/mol).
∆Gsolv ) ∆GPB + ∆Gnp (4)
∆Gnp ) RSASA +  (5)
T∆Ssolute ) T(∆Strans + ∆Srot + ∆Svib)solute (6)
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chain (Table 1). We can appreciate that the ∆Gbind obtained by
the AutoDock software spans from -11.64 to -9.02 kcal/mol.
Other docking solutions (six binding sites; results not shown)
were also mapped on the BACE1 surface, but they all exhibited
significantly less favorable energies of interactions (higher than
-9.02 kcal/mol), suggesting that they were less likely to
correspond to physiologically relevant ligand-binding sites, and
therefore were disregarded. From Table 1, we may argue that
the 12 sites are mostly hydrophobic, with some polar regions.
Binding site 4 (i.e., C4) has the highest apolar buried area and
volume, whereas binding site 10 (i.e., C10) has the lowest total
and apolar buried areas.
As there is no experimental evidence of any significant
conformational change upon binding, during the blind docking
procedure, the ES complex was treated as a rigid body so the
docking algorithms could be applied. Furthermore, such algo-
rithms currently cannot treat a large number of torsional
variables. However, the need to account for the dynamic
behavior of the receptor has long been recognized as a critical
factor in molecular recognition74,75 and in scoring binding
affinities.76 Consequently, to refine the prediction of the blind
docking for the BACE1-INH binding mode, a second stage
by MD simulations was carried out for each of the complexes
identified above.
Binding Mode. In a second stage, 12 MD simulations were
performed, starting from the coordinates of each representative
of the best ranked INH complexes, which were obtained from
the above docking experiment. The complexes were subjected
to 2.0 ns MD simulation with the solvent effect taken into
account through the generalized Born (GB) model. The aim of
this stage was to generate more reasonable binding modes where
the energy optimization and the dynamic flexibility of the
BACE1, the substrate, and the inhibitor were explicitly considered.
To gauge whether the MD simulation was stable and
converged, energetic and structural properties were monitored
during the course of the trajectory. Because the energy
conservation of a system is essential to its stability, and only
the simulation of an energetically stable system can make sense,
the evolutions of the temperature and selected energy terms were
analyzed (see Figure 1-4 in the Supporting Information). These
figures indicate that these energies reach equilibrium in a short
time and oscillate around an average value after about 150 ps.
This rapid convergence is correlated with the overall increase
in mobility of GB simulations relative to explicit solvent
simulations, and this is most probably due to the lack of
frictional forces and the reorganization of water molecules to
balance changes in solute structure. This observation implies
that shorter GB trajectories may be sufficient to cover the
sampling achieved in a longer explicit solvent simulation of
the corresponding molecule.77 Table 1 in the Supporting
Information lists the mean and standard deviation (SD) of these
energies obtained from the last nanosecond of simulation. From
Table 1 in the Supporting Information, we can appreciate that
the unsigned SD is lower than the ∼1.4% from its mean value,
supporting the idea that all systems become energetically well
converged. To explore the dynamic flexibility of these ternary
complexes and to ensure the rationality of the sampling strategy,
the backbone CR root-mean-square deviations (rmsd’s) between
snapshots obtained during the course of the trajectory and the
original starting coordinates were calculated and plotted for each
ternary complex component (i.e., BACE1, substrate and inhibi-
tor, Figures 5-7 in the Supporting Information). As shown in
Figures 5-7 in the Supporting Information, all complexes reach
a plateau before the last nanosecond of simulation. These figures
as well as Table 2 show that while the substrate displays no
significant structural deviation from its starting coordinates (rmsd
e 1.88 Å), both the protein and the INH backbone deviate
somewhat, rmsd e 3.00 Å and rmsd e 3.63 Å, respectively.
However, this is not a major issue that may impact the system
Figure 1. Blind docking results mapped onto the Connolly solvent-
accessible surface of the BACE1, viewed from two different angles.
The 12 best ranked orientations are labeled from C1 to C12.
TABLE 2: Mean Values for the Root-Mean-Square
Displacement (rmsd) (Å) for the Listed Ternary Complexes
C1-C12a
rmsd
complex protein substrate inhibitor
C1 2.23 (0.14) 1.88 (0.17) 2.51 (0.47)
C2 1.89 (0.16) 0.82 (0.17) 1.65 (0.28)
C3 1.90 (0.09) 0.66 (0.12) 2.77 (0.22)
C4 1.40 (0.10) 0.52 (0.11) 2.34 (0.16)
C5 2.65 (0.16) 1.30 (0.27) 1.63 (0.37)
C6 3.00 (0.10) 0.82 (0.14) 1.44 (0.19)
C7 1.79 (0.11) 0.69 (0.16) 1.72 (0.25)
C8 2.14 (0.16) 0.64 (0.09) 2.13 (0.35)
C9 1.93 (0.15) 0.61 (0.09) 3.63 (0.32)
C10 1.95 (0.13) 0.72 (0.09) 3.38 (0.10)
C11 2.11 (0.13) 0.69 (0.11) 1.57 (0.18)
C12 2.12 (0.15) 0.76 (0.15) 2.07 (0.24)
a Values were obtained from the last 1.0 ns of MD. Standard
deviations are indicated in parentheses.
10264 J. Phys. Chem. A, Vol. 114, No. 37, 2010 Gutierrez et al.
stability. Moreover, these results indicate that the systems are
stable as a whole and their flexibility changes to some extent.
A more detailed analysis calculating the root-mean-square
fluctuations (rmsf’s) versus residue number for the 12 BACE1
complexes is illustrated in Figure 8 in the Supporting Informa-
tion. As a general characteristic, the BACE1 structures showed
similar rmsf distribution and similar trends of dynamic features
in all complexes. Except for some obviously high fluctuations,
regions around the catalytic dyad (Asp32 and Asp228) showed
somewhat rigid behavior.
From the above results, we assume well-behaved and
converged simulations that achieve a reasonable amount of
sampling for each component of the ternary complexes (i.e.,
BACE1, substrate, and inhibitor), suggesting that no significant
structural deviations from its starting structures occurred.
Moreover, the calculated rmsd and rmsf at this stage are similar
to previous related systems,78,79 although such reports were
focused on the conformational flexibility of bound and unbound
BACE1-substrate analogues in explicit solvent instead of the
ternary complexes analyzed herein.
Energetic Analysis of the Binding. By the MM-PBSA
analysis,67 the total free energy of binding into electrostatic, van
der Waals, and solute-solvent interactions could be separated,
gaining, thus, additional insights into the physics of the
BACE1-INH association process. For this energetic analysis,
a single trajectory method was performed in order to score the
mode of binding by calculating the binding free energies. For
this analysis, 100 equally spaced snapshots were taken at
intervals of 10 ps from the last 1.0 ns of each MD trajectory.
The binding free energy and the energy components of the
complexes are summarized in Table 3.
According to Table 3, electrostatic (∆Eele) and van der Waals
(∆Evdw) terms in the gas phase provide the major favorable
contributions to the INH binding, whereas polar solvation
energies (∆Gpb) impair the binding. The nonpolar solvation
energies (∆Gnp), which correspond to the burial of SASA upon
binding, barely contribute to the INH binding.
Further insight into the forces involved in BACE1-INH
ternary complex formation can be obtained by analyzing the
electrostatic (∆Gele,tot) and nonelectrostatic (∆Gnp,tot) contribu-
tions in Table 3. As demonstrated by numerous studies, the
electrostatic contribution generally disfavors the docking of
ligand and receptor molecules because the unfavorable change
in the electrostatics of solvation is mostly, but not fully,
compensated by the favorable electrostatics within the resulting
ligand-receptor complex.70,80,81 Indeed, from Table 3, we can
appreciate that, despite the favorable electrostatic energies in
the gas phase (∆Eele), the contributions of polar solvation
energies to binding (∆Gpb) are unfavorable for the 12 complexes,
and the ∆Gele,tot, the sum of ∆Eele and ∆Gpb, does not favor the
binding. Table 3 also suggests that the net result of nonelec-
trostatic interaction (∆Gnp,tot), the sum of ∆Evdw and ∆Gnp, is
favorable for the formation of the 12 complexes, and it should
be noted that this behavior has been proposed previously as a
general trend for noncovalent ligand-receptor associations.82
From the above results, we can conclude that the binding free
energies obtained for these complexes are driven by more
favorable nonpolar interactions rather than by electrostatic
interactions. These results are in agreement with Table 1, which
shows that the located binding sites in the surface of the BACE1
target are mostly hydrophobic.
Although the net ∆Gtot, the sum of enthalpic and desolvation
terms, remained favorable across all of the complexes, covering
a range from -29.73 to -13.16 kcal/mol, the solute entropic
contributions (T∆Stot) are of the same magnitude but unfavor-
able. This opposing interplay between enthalpy and entropy is
known as enthalpy/entropy compensation and is a fundamental
property of noncovalent interactions.83,84 This enthalpy/entropy
compensation results in small changes in ∆G values.85 More
importantly, it is not confined to binding in aqueous solution,86
nor should it be ascribed to errors of measurement.87,88 It arises
because bonding opposes motion and, also reciprocally, motion
opposes bonding. The two effects can be traded off against each
other because the strength of noncovalent bonds is, at room
temperature, comparable to the thermal energies that oppose
them.84
The inclusion of the solute entropic contributions appears to
be important, as evidenced by a substantial reordering of the
binding free energies (∆Gbind) after taking the entropic term into
consideration.
As was recently reviewed,89,90 allostery is a purely thermo-
dynamic phenomenon in which a binding event leads to loss of
freedom of motion of the binding partners, including their
internal motions; thus, it is entropy-unfavorable. Besides, a
disorder-to-order transition generally involves formation of a
more cooperative set of interactions within the protein that
replaces a less cooperative set of interactions between the protein
and the solvent. Then, the added ligand-receptor interactions
are enthalpy-favorable because, during binding, the interactions
get increasingly tighter. Concordantly, the above-mentioned
trend is followed by the complexes analyzed herein, as shown
by the results listed in Table 3.
TABLE 3: Binding Free Energy Components (kcal/mol)a
energy components
complex ∆Eele ∆Evdw ∆Gpb ∆Gnp ∆Gele,tot ∆Gnp,tot ∆Gtot -T∆S ∆GBind ∆∆GBind
C1 -16.62 -36.48 43.28 -5.80 26.66 -42.28 -15.61 23.39 7.78 9.65
C2 -39.12 -56.47 81.50 -8.50 42.38 -64.97 -22.57 26.01 3.44 5.31
C3 -36.65 -69.21 89.78 -9.20 53.13 -78.41 -25.27 25.96 0.69 2.56
C4 -38.42 -45.68 60.79 -6.61 22.37 -52.29 -29.51 27.64 -1.87 0.00
C5 -29.83 -49.33 67.50 -6.76 37.67 -56.09 -17.95 32.05 14.10 15.97
C6 -38.68 -64.69 82.90 -9.27 44.22 -73.96 -29.73 31.93 2.20 4.07
C7 -28.88 -36.20 54.37 -5.93 25.49 -42.13 -16.62 23.90 7.28 9.15
C8 -28.04 -37.31 58.04 -5.88 30.00 -43.19 -13.16 20.96 7.80 9.67
C9 -18.02 -38.34 48.53 -6.51 30.51 -44.85 -14.34 22.77 8.43 10.30
C10 -18.08 -47.45 53.53 -6.28 35.45 -53.73 -18.27 19.83 1.56 3.43
C11 -28.16 -40.34 53.78 -6.37 25.62 -46.71 -21.07 20.99 -0.08 1.79
C12 -44.03 -39.42 62.61 -6.24 18.58 -45.66 -27.06 27.83 0.77 2.64
a Values are averaged over 100 snapshots extracted at regular time intervals during the last 1.0 ns of MD. The energy components were
calculated according to the Methods section. 1 kcal ) 4.18 kJ.
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In this work, the objective was to find the location as well as
the structural and thermodynamic characteristics of the exosite
on the human BACE1, starting from “ad hoc” models. It should
be noted that the inadequacies of the models, the implicit
limitations of the method, and the simplifications in its applica-
tions should be canceled when the relative free energies
(∆∆Gbind) rather than absolute (∆Gbind) energies are calculated.91
Considering the relative binding free energies listed in Table
3, complex 4 (i.e., C4) emerges as the best ranked from the 12
analyzed complexes. This result is highly encouraging because
the identified binding site, where the INH fits the BACE1 target
in complex 4, is in complete agreement with the experimental
observations, suggesting that the docked structure obtained for
complex 4 is an adequate representation of the functional
complex.38 Thus, it is more prudent and certainly not inconsistent
with the above results to analyze deeply the structural charac-
teristics and thermodynamic properties of the binding site in
complex 4 rather than those in all the docked complexes.
However, a second ranked binding site labeled as C11, with
∆∆Gbind ∼1.79 kcal/mol, located ∼48.67 ( 7.51 Å away from
binding site 4 should not be disregarded as another putative
allosteric site. The most important residual contacts of the INH
located at this second ranked binding site C11 are shown in
Table 2 in the Supporting Information.
Mapping the Binding Site in Complex 4. Focusing on the
high affinity binding site identified by the energetic analysis of
binding calculations, we define the binding site in complex 4
as those residues being within approximately 6 Å from any INH
atom. These residues are listed in Table 4. Interestingly, the
great majority of the residues listed in Table 4 are supported
by experimental data.38 However, with the exception of Thr274
that was not found in our calculations, in our dynamic model,
we also identified Gln163, Asp259, Gly273, and Phe322 to be
within the proposed cutoff of 6 Å from the INH.
Figure 2 shows the location of the INH at binding site 4
refined by MD results. We can appreciate that, whereas the
substrate (in red) is located in the binding cleft between the
NH2 lobe (residues 1-180) and COOH lobe (residues 181-385)
and partially covered by the hairpin loop, known as the “flap”
(residues 69-75),28 the INH (in yellow) is located in the COOH
lobe laying over the -sheet that spans from residue 266 to
residue 273 and protrudes to the catalytic cleft. This structural
feature would support the experimental results in which the INH
(and related) peptides inhibited the BACE1-mediated cleavage
of the MBP-APP(547-695) fusion protein in a concentration-
dependent fashion.37 In other words, we argue that the peptide
occupancy at the exosite (i.e., binding site 4) would affect the
binding and cleavage of large substrates that encompass more
residues of the APP protein sequence, probably by steric
hindrances on the catalytic cleft. This is not inconsistent with
an allosteric control of BACE1 because solid evidence that has
been accumulated clearly indicates that allostery can be at play
even in the absence of changes in the shape of a receptor.89,92
To better understand the intermolecular interactions between
each residue of the INH and the residues forming the binding
site in complex 4, Table 5 lists the residue name and number,
distances and contact surfaces of aromatic, stabilizing hydro-
phobic, destabilizing hydrophobic-hydrophilic, and hydrogen
bonding interactions. We can appreciate that the INH residues
Tyr1, Tyr3, and Leu7 may strengthen the binding to the BACE1
at their binding site mainly by hydrogen bonds, whereas Pro2,
Phe4, and Ile5 are involved in aromatic and/or hydrophobic
contacts. However, no interaction takes place between the Pro6
residue on the INH and any BACE1 residue forming the binding
site in complex 4.
To investigate which residues of the binding site identified
in complex 4 determine the binding affinities for the INH, an
inhibitor-residue free energy decomposition analysis70 was
performed. Thus, the most important residues located in the
BACE1 binding site should show the strongest interactions.
TABLE 4: Residues in the Binding Site 4 (i.e., C4) at Less
than 6 Å from the Best Docked Conformation, as Found by
Refined MD (the Matching Positions Are Shown in Bold
Font)
residue binding site
name numbera,b ref 38 MDc
Gln 163 (224) - +
Glu 255 (316) + +
Lys 256 (317) + +
Phe 257 (318) + +
Pro 258 (319) + +
Asp 259 (320) - +
Phe 261 (322) + +
Gly 264 (325) + +
Glu 265 (326) + +
Gln 266 (327) + +
Leu 267 (328) + +
Val 268 (329) + +
Cys 269 (330) + +
Trp 270 (331) + +
Gln 271 (332) + +
Ala 272 (333) + +
Gly 273 (334) - +
Thr 274 (335) + -
Asp 311 (372) + +
Val 312 (373) + +
Ala 313 (374) + +
Ser 315 (376) + +
Asp 317 (378) + +
Asp 318 (379) + +
Cys 319 (380) + +
Tyr 320 (381) + +
Phe 322 (383) - +
a Amino acid numbering based on PDB entry 1M4H. b Amino
acid numbering based on GenBank accession number NP_036236.
c This work.
Figure 2. Refined MD result for complex 4, taken at 2.0 ns of the
MD simulation, mapped onto the Connolly solvent-accessible surface
of the BACE1. The active cleft is shown as the green region, whereas
the residues forming the inhibitor binding site are shown in blue. The
substrate and the inhibitor are shown as red and yellow sticks,
respectively.
10266 J. Phys. Chem. A, Vol. 114, No. 37, 2010 Gutierrez et al.
Figure 3 shows the results of this analysis plotting the ∆Gtot
contribution (which includes van der Waals and electrostatic
interactions, polar solvation contribution, and nonpolar solvation
contribution) versus each BACE1 residue. It should be noted
that these energy values are focused on individual contributions
and are distinct from the calculations of total free energy values
listed in Table 3. According to the free energy decomposition
analysis (Figure 3), the binding between the BACE1 and the
INH located at binding site 4 is driven by selected “hot spots”
that play a major role in BACE1-INH recognition. Interestingly,
the most important residues are, once again, Gln266, Leu267,
Val268, Cys269, Trp270, and Asp317, which were found to be
involved in several interactions of different types with the INH
(see Table 5). In addition, these residues are found in Table 4,
forming the core region of the allosteric binding site, and all of
them are fully supported by experimental results.38
A corresponding analysis referenced to the INH is shown in
Figure 4. Here, as expected, strongly favorable contributions
to the binding are associated with some INH residues at
allosteric binding site 4. However, while Pro2, Ile5, and Pro6
contribute weakly to the binding, Tyr1, Tyr3, Phe4, and Leu7
make strong contributions corroborating the intermolecular
interaction results shown in Table 5.
In summary, from the results shown in Table 5, we can argue
that the higher number of hydrogen bonds, aromatic, and/or
hydrophobic interactions and less hydrophobic-hydrophilic
(destabilizing) interactions between the BACE1 and the INH
residues in complex 4 (i.e., C4) might explain the interaction
energy trend by the INH residues shown in Figure 4.
TABLE 5: Identified Residual Contacts between BACE1 and the INH in the Average Structure from the Last 1.0 ns of MDa
inhibitor residue


















Trp270 3.7 32.3 Phe257 5.4 5.4
hydrophobic-
hydrophobic
Asp317 2.7 36.3 Leu267 4.4 4.9 Pro258 4.2 26.9 Gln266 5.0 8.3 Gln163 4.9 13.5





Thr314 5.6 8.5 Cys269 2.9 59.5 Gln266 5.4 1.7 Pro258 5.1 11.0 Gln266 3.7 8.1
Asp317 2.7 36.3 Leu267 3.9 3.9 Gln266 5.0 8.3 Leu267 3.0 40.1
Val268 4.5 8.7 Lys321 5.2 1.0
hydrogen bond Trp270 3.9 4.5 Cys269 2.9 59.5 Leu267 3.0 40.1
Asp317 2.7 36.3 Asp311 4.4 25.3
a Abbreviations: dist., atomic distance (Å); surf., surface contact area (Å2).
Figure 3. Histogram of interaction energies partitioned with respect to the BACE1 amino acids in complex 4 (i.e., C4). The x-axis denotes the
residue number of BACE1, and the y-axis denotes the energy between the inhibitor and specific residues. The reference state is separate BACE1
and INH, with negative values favorable and positive values unfavorable to binding.
Figure 4. Histogram of interaction energies partitioned with respect
to the inhibitor (i.e., INH) amino acids. The x-axis denotes the residue
number of INH, and the y-axis denotes the energy between the inhibitor
and the BACE upon binding. The reference state is the unbound INH,
with negative values favorable and positive values unfavorable to
binding.
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To our knowledge, a complete structural description for the
exosite associated with BACE1 has not been reported yet. Only
partial information about the location and a list of the amino
acids located at 6 Å from the inhibitor might be obtained from
ref 38 sections 0058. From our results, a complete structural
description for this exosite, including the different interaction
stabilizing the BACE1-INH complex, was obtained. The full
coordinates of this complex are available from the authors upon
request.
4. Conclusions
Twelve binding pockets were identified on the surface of
BACE1 by blind docking studies. MD were performed to refine
the docked structures and to investigate the binding mode on
each ternary complex. The results indicate that the systems are
stable as a whole and their flexibility changes to some extent.
The calculations of binding free energies for the 12 complexes
using MM-PBSA methods showed that van der Waals interac-
tions dominated the binding of these complexes. On the other
hand, the best ranked ternary complex showed convincing
consistency with experimentally determined data described in
the literature.38
In agreement with the structure of the INH peptide obtained
from an X-ray study,38 residues Glu255-Pro258, Phe261,
Gly264-Ala272, Asp311-Ala313, Ser315, and Asp317-Tyr320
are located within ∼6 Å from the INH at the exosite binding
site.38 The simulations revealed that the topological occupancy
of the INH at the BACE1 exosite would affect the binding and
cleavage of large substrates that encompass more APP protein
residues by steric hindrances on the catalytic cleft.
Energy decomposition on a per-residue basis for the best
ranked complex (i.e., C4) showed that residues Gln266, Leu267,
Val268, Cys269, Trp270. and Asp317 can be identified as hot
spots to the BACE1-INH ternary complex formation. We found
that favorable interactions are produced between the BACE1
and the INH residues Tyr1, Tyr3, Phe4, and Leu7. In addition,
on the basis of the hydrogen bond analysis, the hydrogen bonds
formed between the INH peptide, residues Tyr1, Tyr3, and Leu7,
with the BACE1 residues Leu267, Cys269, Trp270, Asp311,
and Asp 317 were shown to strengthen the binding of the
BACE1-INH complex.
Our results suggest that the design of new and more potent
allosteric inhibitors can be synthesized replacing INH positions
Pro2, Ile5, and/or Pro6 in order to optimize the affinity for the
exosite. Since the binding affinity is determined by the Gibbs
energy Ka ) exp(-∆G/RT) and ∆G is given by ∆G ) ∆H -
T∆S,93 it is apparent that binding optimization can be ac-
complished by making either ∆H more negative or ∆S more
positive, or by an appropriate combination of both. The above
could allow us to propose one of the following modifications
on the INH: (i) to replace positions 2, 5, and/or 6 with low
desolvation energy amino acids, like Ala, Ile, Leu, and Val;
(ii) to replace these positions with high degree of freedom amino
acids, like Ile, Leu, and Val; or (iii) to apply an appropriate
combination of both.
This is the first report on a molecular modeling approach on
an exosite associated with BACE1 carried out from the
experimental data available in the literature.37,38 We believe that
understanding the exosite interactions at the atomic level may
help for the development of novel BACE1 inhibitors with better
potency and efficacy, being useful as chemotherapeutic agents
for the treatment of Alzheimer’s disease. Moreover, the results
of this study clearly indicate the significance of the applied
computational methods to provide insight into protein complexes
on an atomic level even when limited experimental information
is available.
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(40) Grüninger-Leitch, F. J. Biol. Chem. 2002, 277, 4687–4693.
(41) Gordon, J. C.; Myers, J. B.; Folta, T.; Shoja, V.; Heath, L. S.;
Onufriev, A. Nucleic Acids Res. 2005, 33, 368–71.
(42) Anandakrishnan, R.; Onufriev, A. J. Comput. Biol. 2008, 15, 165–
184.
(43) Bashford, D.; Karplus, M. Biochemistry 1990, 29, 10219–10225.
(44) Park, H.; Lee, S. J. Am. Chem. Soc. 2003, 125, 16416–16422.
(45) Rajamani, R.; Reynolds, C. H. J. Med. Chem. 2004, 47, 5159–
5166.
(46) Suguna, K.; Padlan, E. A.; Smith, C. W.; Carlson, W. D.; Davies,
D. R. Proc. Natl. Acad. Sci. U.S.A. 1987, 84, 7009–7013.
(47) Davies, D. R. Biophys. Chem. 1990, 19, 189–215.
(48) Coupez, B.; Lewis, R. A. B. Curr. Med. Chem. 2006, 13, 2981–
2993.
(49) Alonso, H. A.; Bliznyuk, A. A.; Gready, J. E. Med. Res. ReV. 1996,
26, 531–568.
(50) (a) Goodsell, D. S.; Morris, G. M.; Olson, A. J. J. Mol. Recognit.
1996, 9, 1–5. (b) Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.;
Hart, W. E.; Belew, R. K.; Olson, A. J. J. Comput. Chem. 1998, 19, 1639–
1662.
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